$1.43
0.021.42%
Last update: 9:18 AM
15 minutes delayed
Comments
Loading...
Immunic
IMUXNASDAQ
Immunic (NASDAQ:IMUX) Stock, Analyst Ratings, Price Targets, Forecasts
Immunic Inc has a consensus price target of $19.43 based on the ratings of 7 analysts. The high is $35 issued by Aegis Capital on August 8, 2022. The low is $5 issued by SVB Leerink on October 21, 2022. The 3 most-recent analyst ratings were released by Piper Sandler, Brookline Capital, and Wedbush on July 16, 2024, April 5, 2024, and October 10, 2023, respectively. With an average price target of $15 between Piper Sandler, Brookline Capital, and Wedbush, there's an implied 927.40% upside for Immunic Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Piper Sandler
Brookline Capital
Wedbush
SVB Leerink
HC Wainwright & Co.
1calculated from analyst ratings
Analyst Ratings for Immunic
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 07/16/2024 | Buy Now | 1817.81% | Piper Sandler | Yasmeen Rahimi | $28 → $28 | Reiterates | Overweight → Overweight | Get Alert |
| 04/05/2024 | Buy Now | 584.93% | Brookline Capital | Tyler Bussian | → $10 | Initiates | → Buy | Get Alert |
| 10/10/2023 | Buy Now | 379.45% | Wedbush | Andreas Argyrides | $5 → $7 | Maintains | Outperform | Get Alert |
| 07/27/2023 | Buy Now | 242.47% | Wedbush | Andreas Argyrides | → $5 | Reiterates | Outperform → Outperform | Get Alert |
| 01/31/2023 | Buy Now | 242.47% | Wedbush | Andreas Argyrides | → $5 | Assumes | → Outperform | Get Alert |
| 10/21/2022 | Buy Now | 242.47% | SVB Leerink | Thomas Smith | $9 → $5 | Downgrade | Outperform → Market Perform | Get Alert |
| 09/19/2022 | Buy Now | 1680.82% | HC Wainwright & Co. | Gobind Singh | → $26 | Assumes | → Buy | Get Alert |
| 08/08/2022 | Buy Now | 2297.26% | Aegis Capital | Nathan Weinstein | $40 → $35 | Maintains | Buy | Get Alert |
| 06/03/2022 | Buy Now | 516.44% | SVB Leerink | Thomas Smith | $45 → $9 | Maintains | Outperform | Get Alert |
| 05/18/2022 | Buy Now | 2571.23% | Piper Sandler | Yasmeen Rahimi | $71 → $39 | Maintains | Overweight | Get Alert |
| 09/07/2021 | Buy Now | 1612.33% | HC Wainwright & Co. | Raghuram Selvaraju | — | Maintains | Buy | Get Alert |
FAQ
What is the target price for Immunic (IMUX) stock?
The latest price target for Immunic (NASDAQ:IMUX) was reported by Piper Sandler on July 16, 2024. The analyst firm set a price target for $28.00 expecting IMUX to rise to within 12 months (a possible 1858.04% upside). 4 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Immunic (IMUX)?
The latest analyst rating for Immunic (NASDAQ:IMUX) was provided by Piper Sandler, and Immunic reiterated their overweight rating.
When was the last upgrade for Immunic (IMUX)?
There is no last upgrade for Immunic
When was the last downgrade for Immunic (IMUX)?
The last downgrade for Immunic Inc happened on October 21, 2022 when SVB Leerink changed their price target from $9 to $5 for Immunic Inc.
When is the next analyst rating going to be posted or updated for Immunic (IMUX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Immunic, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Immunic was filed on July 16, 2024 so you should expect the next rating to be made available sometime around July 16, 2025.
Is the Analyst Rating Immunic (IMUX) correct?
While ratings are subjective and will change, the latest Immunic (IMUX) rating was a reiterated with a price target of $28.00 to $28.00. The current price Immunic (IMUX) is trading at is $1.43, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.